![Bruno Lucidi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bruno Lucidi
Direttore/Membro del Consiglio presso ATEA PHARMACEUTICALS, INC.
Patrimonio netto: 183 500 $ in data 31/05/2024
Posizioni attive di Bruno Lucidi
Società | Posizione | Inizio | Fine |
---|---|---|---|
ATEA PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 01/09/2014 | - |
Independent Dir/Board Member | 01/09/2014 | - |
Storia della carriera di Bruno Lucidi
Precedenti posizioni note di Bruno Lucidi
Società | Posizione | Inizio | Fine |
---|---|---|---|
MINK THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 23/10/2017 | 01/09/2019 |
Amministratore Delegato | 23/10/2017 | 01/09/2019 | |
Karolinska Development AB (Private Equity)
![]() Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Amministratore Delegato | 01/10/2014 | 31/01/2015 |
Akinion Pharmaceuticals AB
![]() Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Amministratore Delegato | - | - |
Aprea Therapeutics AB
![]() Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Amministratore Delegato | - | - |
KDev Oncology AB
![]() KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Amministratore Delegato | 08/09/2014 | - |
KAROLINSKA DEVELOPMENT AB | Amministratore Delegato | 15/10/2014 | - |
Statistiche
Distribuzione geografica
Svezia | 6 |
Stati Uniti | 3 |
Posizioni
Chief Executive Officer | 6 |
Director/Board Member | 2 |
Independent Dir/Board Member | 1 |
Settori
Health Technology | 5 |
Finance | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
KAROLINSKA DEVELOPMENT AB | Finance |
MINK THERAPEUTICS, INC. | Health Technology |
ATEA PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 4 |
---|---|
KDev Oncology AB
![]() KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Commercial Services |
Aprea Therapeutics AB
![]() Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Akinion Pharmaceuticals AB
![]() Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Health Technology |
Karolinska Development AB (Private Equity)
![]() Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Finance |
- Borsa valori
- Insiders
- Bruno Lucidi
- Esperienza